###### Strengths and limitations of this study

-   This large systematic review (N=148 studies) adds to the existing literature by providing updated results and new data regarding the frequency and consistency of vitamin K antagonists (VKA) control measure reporting.

-   While the previous review by Fitzmaurice *et al* included studies of all VKA indications; ours evaluated atrial fibrillation (AF) and VTE studies only.

-   Unlike previous reviews, our systematic review examined VKA control measure reporting over time and differences in reporting between AF and VTE studies and randomised trials and observational studies. In addition, we explored the way in which VKA control measures are concomitantly reported in studies.

Introduction {#s1}
============

Adjusted-dose vitamin K antagonists (VKAs) are frequently used, and are the standard-of-care anticoagulants that most new oral anticoagulants for the prevention of thrombotic events in patients with atrial fibrillation (AF) and following venous thromboembolism (VTE) are compared with.[@R1] VKAs have substantial evidence from clinical trials supporting their efficacy, and their use is endorsed by multiple national guidelines[@R11] [@R12]; however, they are often underused due to difficulty in maintaining the international normalised ratio (INR) in the narrow therapeutic range (often 2.0--3.0).[@R13] [@R14]

Fitzmaurice *et al*[@R15] performed a systematic review of studies published between 1995 and 1999 in order to evaluate the manner in which VKA control was reported and to provide recommendations for reporting of VKA control measures (parameters used to summarise the level of anticoagulation). Their review found that a wide range of measures had been used in the literature, but with little consistency between studies. Since studies also suggest different VKA control measures (eg, percentage of time spent in range, proportion of tests in range, point prevalence) used in the same population can result in different conclusions regarding the quality of VKA control,[@R16] researchers recommended ≥2 VKA control measures be reported per study.

In order to aid researchers (eg, clinical trialists and systematic reviewers) and other end users, we performed a systematic review to assess the degree of standardisation in VKA control measure reporting that has occurred in AF and VTE studies since the publication of the paper by Fitzmaurice *et al*; and to determine whether their recommendation of reporting ≥2 control measures has been widely employed.

Methods {#s2}
=======

A systematic review of MEDLINE, CENTRAL and EMBASE (from 2000 to June 2013) was conducted to identify published studies (English full-text randomised controlled trials, prospective cohort studies or retrospective analyses) including at least one dose-adjusted VKA treatment arm and reporting a minimum of one VKA control measure in adult patients being treated for AF or VTE as their primary reason for anticoagulation. Our search strategy for MEDLINE (PubMed) is provided in online supplementary appendix 1. Studies were excluded if they included \<50 patients or planned to treat patients for \<3 months. Manual backwards citation tracking of references from identified studies and review articles was also performed to identify additional relevant studies. All citations were screened by two independent investigators (ESM and J-SS) with discrepancies resolved by a third investigator (CIC).

Through the use of a standardised data extraction tool, we independently extracted all data (ESM, J-SS and JH), with disagreements resolved by a separate investigator (CIC). Collected study-level data included: study identifier and year of publication; indication(s) for VKA therapy; sample size; study design (prospective, retrospective or randomised study); duration of VKA treatment; mean age of participants; and the type(s) of VKA used. The types of VKA control measures reported were also extracted from each study. These included (but were not limited to): percentage of time in range (target international normalised ratio (TTR), calculated using Rosendaal\'s linear interpolation method[@R19]), below and/or above range, TTR in an extended range (ie, 1.8--3.2) and extreme ranges (ie, \<1.5 and/or \>5.0); proportion of INR measurements in range (PINRR), below and/or above extreme range; mean/median INR; mean/median VKA dose; frequency of INR monitoring (number of INR measures per patient over the course of the study); INR variability; INR monitoring interval (number of days between each INR measure); point prevalence (eg, the proportion of patients in range and/or out of range, proportion of patients in range \>50% of time or proportion of patients with ≥50% of INR measures \<3.0); number of VKA dosage changes; INR measure after a previously subtherapeutic or supratherapeutic INR; proportion of patients with ≥1 INR measure below range after reaching an adequate INR; number of days until the next INR measure after an extreme measure; proportion of days with treatment stability (two consecutive INR measures in range); days to reach a therapeutic INR; mean time until stable and minimum and maximum INR values per patient.

The types of measures reported were summarised and displayed using tables and figures, and the proportion of studies reporting ≥2 measures along with the mean number of measures per study (±SD) were reported for all identified studies. We also compared these same end points between select study subgroups (primary indication for anticoagulation (AF vs VTE); study design (randomised trial vs observational study); and year of publication (2000--2003 vs 2004--2013)). The year categorisations were chosen based on the year of publication of the review by Fitzmaurice *et al*.[@R15] Finally, in order to assess the concomitant use of VKA control measures within studies, a diagram depicting per study measure linkages was created.

Between-group comparisons were made using χ^2^ tests (or Fisher\'s exact tests, where appropriate) for categorical data and unpaired t tests for continuous data. A p value of \<0.05 was considered statistically significant in all situations. Statistical analysis was performed using SPSS V.17.0 (SPSS Inc, Chicago, Illinois, USA).

Results {#s3}
=======

Of the 5301 citations initially identified, 1119 full-text articles were reviewed for inclusion. A total of 148 studies met all inclusion and exclusion criteria and were included in the analysis ([figure 1](#BMJOPEN2014005379F1){ref-type="fig"}, [table 1](#BMJOPEN2014005379TB1){ref-type="table"}).[@R1] [@R18] [@R20] Of note, 112 VKA studies were excluded from our systematic review because they did not report a VKA control measure although study participants were receiving a VKA for AF or VTE as their primary reason for treatment for greater than 3 months.

###### 

Studies reporting at least one VKA quality control measure

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                 Disease state   Study design   VKA-treated N   VKA studied   Target INR           TTR, %   PINRR, %   Mean/median INR   Mean/median dose   Monitoring frequency   INR variability   INR testing interval, days\*   PPIR   Other\*
  ------------------------------------- --------------- -------------- --------------- ------------- -------------------- -------- ---------- ----------------- ------------------ ---------------------- ----------------- ------------------------------ ------ ---------
  Abdelhafiz and Wheeldon[@R20]         AF              PD             402             W             2--3                 •                   •                                    •                      •                                                       

  Abdelhafiz and Wheeldon[@R21]         AF              PD             402             W             2--3                 •                   •                                    •                      •                                                       

  Agnelli *et al* [@R22]                DVT             RCT            134             W,A           2--3                 •                                                                                                                                       

  Agnelli *et al *[@R23]                PE              RCT            165             W,A           2--3                 •                                                                                                                                       

  Agnelli *et al *[@R24]                DVT             RCT            126             W,A,P         2--3                 •                                                                                                                                       

  Agnelli *et al *[@R7]                 VTE             RCT            2704                          2--3                 •                                                                                                                                       

  Albers *et al *[@R25]                 AF              RCT            1962            W             2--3                 •        •                                                                                                                       •      

  Amiwero *et al *[@R26]                VTE             RCT            126             W             2--3                 •                   •                                                                                                            •      

  Anderson[@R27]                        AF              RD             87              W             2--3                          •                                               •                                                                              

  Ansell *et al *[@R18]                 AF              RD             1511            W, A, F       2--3                 •        •                                               •                      •                 •                                     •

  Aujesky *et al *[@R28]                PE              RCT            339             W,A,P,F       2--3                 •                                                                                                                                       

  Bona *et al *[@R29]                   VTE             PD             98              W             2--3                 •                                                                                                                                       

  Boulanger *et al *[@R30]              AF              RD             6431            W             2--3                 •                                                        •                                        •                              •      

  Büller *et al *[@R31]                 PE              RCT            2184            --            2--3                 •                                                                                                                                       

  Büller *et al *[@R32]                 DVT             RCT            137             W,A,P,F       2--3                          •                                               •                                                                              

  Büller *[et al ]{.ul}*[@R33]          PE              RCT            1595            W             2--3                 •                                                                                                                                       

  Burton *et al *[@R34]                 AF              RD             259             W             2--3                 •                   •                                    •                                                                              

  Cafolla *et al *[@R35]                AF/VTE          PD             871             W,A, other    2--3                 •                                                                                                                                       

  Cafolla *et al *[@R36]                AF              PD             112             W             2--3/\               •                                     •                                         •                                                       
                                                                                                     1.5--2.5                                                                                                                                                     

  Campbell *et al *[@R37]               VTE             RCT            749             W             2--3.5                                                                                                                                                •      

  Cheung *et al *[@R38]                 AF              RD             555             W             1.5--3               •                                                                                                                                       

  Chitsike *et al *[@R39]               VTE             PD             349             W             2--3                 •                                                                                                                                •      

  Chung *et al *[@R40]                  AF              RCT            75              W             2--3                 •                                                                                                                                       

  Coleman *et al *[@R41]                AF              PD             65              W             2--3                 •                                                                                                                                       •

  Connolly *et al *[@R42]               AF              RCT            3371            --            2--3                 •                                                                                                                                       

  Connolly *et al *[@R43]               AF              RCT            3371            --            2--3                 •                                                                                                                                       

  Connolly*et al *[@R6]                 AF              RCT            6022            W             2--3                 •                                                                                                                                       

  Copland *et al *[@R44]                AF              RD             328             W             1.8--3.3                                                   •                  •                                                                              

  Currie *et al *[@R45]                 AF              RD             1513            W             2--3                 •        •                            •                  •                      •                                                       •

  Daskalopoulos *et al *[@R46]          DVT             RCT            52              A             2--3                                                       •                                                                                                 

  Dimberg *et al *[@R47]                AF              RD             791             W             2--3                 •                                                                                                 •                                     

  Douketis *et al *[@R48]               VTE             RCT            1021            --            2--3                                                       •                                                                                                 

  Easton *et al *[@R49]                 AF              RCT            1643            W             2--3                 •                                                                                                                                       

  The Einstein Investigators[@R49a]     DVT             RCT            1718            W,A           2--3                 •                                                                                                                                       

  The Einstein Investigators[@R49b]     PE              RCT            2413            W,A           2--3                 •                                                                                                                                       

  Ellis *et al *[@R50]                  AF              RCT            66              T             2--3                 •                   •                 •                                                                                          •      

  Evans *et al *[@R51]                  AF              PD             288             W             2--3                 •        •                                                                                                                              

  Evans *et al *[@R52]                  AF              PD             214             W             2--3                 •        •                                                                                                                              

  Ezekowitz *et al *[@R53]              AF              RCT            70              W             2--3                 •                                                                                                                                       

  Ezekowitz *et al *[@R54]              AF              RCT            6022            W             2--3                 •                                                                                                                                       

  Fiessinger *et al *[@R55]             VTE             RCT            1249            W             2--3                 •                                                                                                                                       

  Ford *et al *[@R56]                   AF              RCT            3665            W             2--3                 •        •                                                                                                                              

  Gadisseur *et al *[@R57]              DVT             PD             266             A,P           2.5--3.5             •        •                                                                                                                              

  Gallagher *et al *[@R58]              AF              RD             18 113          W             2--3                 •                                                        •                                                                              

  Gallagher *et al *[@R59]              VTE             RD             10 381          W,A,P         2--3                 •                                                        •                                                                              

  Garcia *et al *[@R60]                 AF              RCT            9081            W             2--3                 •                                                                                                                                       

  Go *et al *[@R61]                     AF              RD             6320            W             2--3                 •                                                        •                                                                              

  Gomberg-Maitland *et al *[@R6][@R2]   AF              RCT            3624            W             2--3                 •                                                                                                                                       

  Granger *et al *[@R8]                 AF              RCT            9081            W             2--3                 •                                                                                                                                       

  Hankey *et al *[@R63]                 AF              RCT            7133            W             2--3                 •                                                                                                                                       

  Heidinger *et al *[@R64]              AF/DVT          PD             1375            --            2--3                                                       •                                                                                                 

  Ho *et al *[@R65]                     AF              RD             476             W             2--3                 •        •                                                                                                                       •      

  Hokusai-VTE Investigators[@R65a]      VTE             RCT            4122            W             2--3                 •                                                                                                                                       

  Holmes *et al *[@R66]                 AF              RCT            244             W             2--3                 •                                                                                                                                       

  Hori *et al *[@R67]                   AF              RCT            108             W             2--3/\               •                                                                                                                                       
                                                                                                     2--2.6                                                                                                                                                       

  Hori *et al *[@R68]                   AF              RCT            639             W             2--3/\                                                     •                                                                                                 
                                                                                                     1.6--2.6                                                                                                                                                     

  Hutten *et al *[@R69]                 VTE             RCT            1039            --            2--3                 •                                                                                                                                       

  Hylek *et al *[@R70]                  AF              PD             472             W             2--3                 •                                                        •                                                                              

  Hylek *et al *[@R71]                  AF              RCT            3665            W             2--3                 •                                                                                                                                •      

  Jacobs *et al *[@R72]                 AF              RD             90              W             2--3                 •                                                                                                 •                                     

  Jones *et al *[@R73]                  AF              RD             2223            W             2--3                 •        •                            •                  •                                        •                                     

  Kalra *et al *[@R74]                  AF              PD             167             W             2--3                 •                                                                                                 •                                     

  Kearon *et al *[@R75]                 VTE             RCT            738             W             2--3/\               •        •                                                                                        •                                     
                                                                                                     1.5--1.9                                                                                                                                                     

  Kearon *et al *[@R76]                 VTE             RCT            81              W             2--3                 •        •                                                                                                                              

  Kearon *et al *[@R77]                 VTE             RCT            703             W             2--3                 •                                                                                                                                       

  Kim *et al *[@R78]                    AF              RD             129             W             2--3                 •                   •                 •                  •                                        •                                     

  Kim *et al *[@R79]                    AF/VTE          PD             646             W             2--3                 •                                                                                                                                       

  Kulo *et al *[@R80]                   AF              PD/RD          117             W,A           2--3                 •        •          •                 •                  •                                                                              

  Kulo *et al *[@R81]                   AF              PD/RD          117             W,A           2--3                 •                                     •                  •                                        •                              •      

  Kurtoglu *et al *[@R82]               DVT             PD             246             W             2--3                 •                                                                                                                                       •

  Lee *et al *[@R83]                    AF              PD/RD          200             W             2--3                 •        •                                                                                                                       •      

  Lip *et al *[@R84]                    AF              RCT            318             --            2--3                                                                                                                                                  •      

  Lopez-Beret *et al *[@R85]            DVT             RCT            77              A             2--3                                                       •                                                                                                 

  Malik and Taylor [@R86]               AF/VTE          RD             328             W             2--3                 •                                                                                                                                       

  Mant *et al *[@R87]                   AF              RCT            488             W             2--3                 •        •                                                                                                                              

  Matchar *et al *[@R88]                AF              RCT            363             W             2--3                 •                                                                                                 •                                     

  Matchar [@R89]                        AF              RCT            363             W             2--3                 •                                                                                                 •                                     

  McBride *et al *[@R90]                AF              PD             324             W             2--3                 •                                                                                                                                       

  McCormick *et al *[@R91]              AF              RD             174             W             2--3                 •                                                                                                 •                                     

  Melamed *et al *[@R92]                AF              RD             906             W             2--3                 •                                                        •                                                                       •      

  Menzin *et al *[@R93]                 AF              RD             600             W             2--3                 •                                                        •                                                                              

  Morgan *et al *[@R94]                 AF              RD             2235            W             2--3                 •                                                        •                                                                              

  Naganuma *et al *[@R95]               AF              RD             845             W             1.5--2.5             •                                                                                                                                       

  Nakatani *et al *[@R96]               AF              R              95              W             2--3/\               •                                     •                                         •                 •                                     
                                                                                                     1.6--2.6                                                                                                                                                     

  Neree *et al *[@R97]                  AF              RD             395             W,P,A         2--3                 •                                     •                  •                                                                       •      

  Nichol *et al *[@R98]                 AF              RD             1107            W             2--3                 •                                                                                                 •                                     

  Nieuwlaat *et al *[@R99]              AF              RCT            266             --            2--3                 •        •                                                                                        •                                     

  Njaastad *et al *[@R100]              AF/VTE          RD             936             W             2--3                 •                                                                                                                                       

  Nozawa *et al *[@R101]                AF              PD             156             W             1.6--1.9                      •                                               •                      •                                                       •

  Obata *et al *[@R102]                 AF              RD             110             W             1.6--2.6             •        •          •                                    •                      •                 •                                     

  Ogawa *et al *[@R103]                 AF              RCT            74              W             2--3/\                                                                                                                                                •      
                                                                                                     2--2.6                                                                                                                                                       

  Okumura *et al *[@R104]               AF              PD             501             W             2--3/\               •                   •                                                                             •                                     
                                                                                                     1.6--2.6                                                                                                                                                     

  Olsson [@R105]                        AF              RCT            1703            W             2--3                 •        •                                                                                                                              

  Olsson *et al *[@R106]                AF              RCT            83              W             2--3                 •                                                                                                                                       

  Ombandza-Moussa *et al *[@R107]       VTE             RD             81              --            --                            •                                                                                                                              

  Ono and Fujita[@R108]                 AF              PD             63              W             1.5--2.5             •        •                                                                                        •                                     

  Palareti *et al *[@R109]              VTE             PD             733             W, A          2--3                 •                                                                                                 •                                     

  Palareti *et al *[@R110]              VTE             PD             297             W, A          2--3                 •                                                                                                                                       

  Patel *et al *^1^                     AF              RCT            7133            W             2--3                 •                                                                                                                                       

  Pengo *et al *[@R111]                 AF              PD             433             W,A           2--3                 •        •          •                                                                             •                                     

  Pengo *et al *[@R112]                 AF              RCT            267             W             2--3/\               •        •                                                                                        •                                     
                                                                                                     1.5--2.0                                                                                                                                                     

  Perez-de-Llano[@R113]                 PE              RCT            50              A             2--3                                                       •                                                                                                 

  Perez-Gomez[@R114]                    AF              RCT            479             A             2--3                 •        •          •                                    •                                        •                                     

  Perez-Gomez[@R115]                    AF              RCT            91              --            2--3                 •        •          •                                    •                                        •                                     

  Perez-Gomez[@R116]                    AF              RCT            496             --            2--3                 •        •          •                                                                                                                   

  PERSIST Investigators[@R117]          DVT             RCT            132             W             2--3                                                       •                  •                                                                              

  Petersen *et al *[@R118]              AF              RCT            67              W             2--3                                                                                                                                                  •      

  Poli *et al *[@R119]                  VTE             PD             182             W             2--3                 •                   •                                                                                                                   

  Poli *et al *[@R120]                  AF              PD             290             --            2--3                 •                                                                                                                                       

  Poli *et al *[@R121]                  AF              PD             783             W             2--3                 •                   •                                                                                                                   

  Poli *et al *[@R12][@R2]              AF              PD             780             W             2--3                 •                   •                                                                                                                   

  Poli *et al *[@R12][@R3]              AF              PD             578             --            2--3                 •        •                                                                                                                              

  Poller *et al *[@R124]                AF/VTE          RCT            9148            W, A, P       2--3                 •                                                                                                                                       

  Prandoni (Galilei) *et al *[@R125]    VTE             RCT            720             W             2--3                                                                                                                                                  •      

  Prandoni *et al *[@R126]              DVT             RCT            180             --            2--3                                                                                                                                                  •      

  Ridker *et al *[@R127]                VTE             RCT            255             W             1.5--2                        •          •                                                                                                                   

  Rombouts *et al *[@R128]              AF              RCT            104             P             2--3.5               •                                                                                                                                       

  Sadanaga *et al *[@R129]              AF              PD             269             W             1.5--3                        •                                                                                                                       •      

  Samsa *et al *[@R130]                 AF              RD             660             W             2--3                 •                                     •                  •                                        •                                     

  Sarawate *et al *[@R131]              AF              PD             470             W             2--3                 •                                                                                                                                       

  Schulman *et al *[@R4]                VTE             RCT            1265            W             2--3                 •                                                        •                                                                              

  Schulman *et al *[@R5]                VTE             RCT            1426            W             2--3                 •                                                                                                                                       

  Sconce *et al *[@R132]                AF              RCT            70              W             2--3                 •                   •                                                           •                                                       

  Shalev *et al *[@R133]                AF              RD             4408            W             2--3                 •                                     •                  •                                        •                                     

  Shen *et al *[@R134]                  AF              RD             18 867          W             2--3                 •                                                        •                                                                              

  Shen *et al *[@R135]                  AF              RD             8992            W             2--3                 •                                                        •                                                                              

  Sullivan *et al *[@R136]              AF              RCT            4060            W             2--3                 •                                                                                                                                       

  Suzuki *et al *[@R137]                AF              PD             667             W             1.6--2.6                      •                                                                                                                              

  Tincani *et al *[@R138]               AF              PD             90              W,A           2--3                 •                   •                                                                                                                   

  van Bladel *et al *[@R139]            PE              PD             86              A             2--3.5               •                                                                                                                                       

  van Dongen *et al *[@R140]            DVT             PD             244             --            2--3                 •                                                                                                                                •      

  van Geest-Daalderop *et al *[@R141]   AF              RD             284             A             2--3.5               •                                                                                                                                       

  van Gogh Investigators[@R141a]        VTE             RCT            2572            W,A           2--3                 •                                                                                                                                       •

  Van Spall *et al *[@R143]             AF              RCT            6022            W             2--3                 •                                                        •                                                                              

  Veeger *et al *[@R144]                VTE             RD             2304            A             2--3.5               •        •                                               •                                        •                              •      

  Vene *et al *[@R145]                  AF              PD             113             W             2--3                          •                                                                                                                              

  Voller *et al *[@R146]                AF              RCT            202             --            2--3                 •                                     •                  •                      •                                                       

  Walker *et al *[@R147]                AF              RD             84              W             2--3                 •                                                                                                                                       •

  Weimar *et al *[@R148]                AF              PD             252             W             2--3                                                                                                                   •                                     •

  Weitz *et al *[@R149]                 AF              RCT            250             W             2--3                 •                                                                                                                                       •

  White *et al *[@R150]                 AF              RCT            3587            W             2--3                 •                                                        •                                        •                              •      

  Wieloch *et al *[@R151]               AF/VTE          RD             15 264          W             2--3                 •                                     •                  •                                                                              

  Willey *et al *[@R152]                VTE             RD             225             W             2--3                 •        •                                               •                                                                              

  Wyse *et al *[@R153]                  AF              RCT            4060            W             2--3                          •                                                                                                                              

  Yamaguchi[@R154]                      AF              RCT            115             W             2.2--3.5/ 1.5--2.1            •                                                                                                                              

  Yamashita *et al *[@R155]             AF              RCT            129             W             2--3/\               •                                                                                                                                       
                                                                                                     1.6--2.6                                                                                                                                                     

  Yasaka *et al *[@R156]                AF              PD             88              W             --                            •                                                                                                                              

  Yousef *et al *[@R157]                AF              RD             739             W             2--3                          •                            •                  •                                        •                                     
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*'Other' includes: number of dosage changes; INR measure after a previously subtherapeutic or supratherapeutic INR; proportion of patients with ≥1INR measure below range after reaching an adequate INR; number of days until the next INR measure after an extreme measure; proportion of days with treatment stability (two consecutive INR measures in range); days to reach a therapeutic INR; mean time until stable (6 months within target INR range); minimum and maximum INR values per patient.

-- Indicates data not reported.

A, acenocoumarol; AF, atrial fibrillation; DVT, deep vein thrombosis; F, fluindione; INR, international normalised ratio; N, sample size; PD, prospective design; P, phenprocoumon; PINRR, proportion of INR measures in range; PPIR, proportion of patients in range; RCT, randomised controlled trial; RD, retrospective design; T, tecarfarin; TTR, time in therapeutic range; VKA, vitamin K antagonist; VTE, venous thromboembolism; W, warfarin.

![Results of the literature search. AF, atrial fibrillation; CCTR, Cochrane controlled trials register; RCT, randomised controlled trial; VKA, vitamin K antagonist; VTE, venous thromboembolism.](bmjopen2014005379f01){#BMJOPEN2014005379F1}

Overall, 57% of studies reported ≥2 VKA control measures (mean/study=2.13±1.36; [table 2](#BMJOPEN2014005379TB2){ref-type="table"}). TTR was the most common measure reported (79%), and in a little more than half of these studies, was accompanied by the proportion of time above and/or below range. Other common metrics (used in ≥20% of studies) included mean/median INR, frequency of INR monitoring, INR testing interval and the proportion of patients in/out of range. Subgroup analysis found AF studies were 1.7-fold more likely than VTE studies ([table 3](#BMJOPEN2014005379TB3){ref-type="table"}), observational studies were more than twice as likely as randomised trials (p≤0.05 for all comparisons; [table 4](#BMJOPEN2014005379TB4){ref-type="table"}) and recently published studies were 70% more likely than older studies (2000--2003; [table 5](#BMJOPEN2014005379TB5){ref-type="table"}) to report ≥2 control measures. Moreover, the AF, observational and later time period study subgroups were also more likely to report a greater absolute number of measures per study (p\<0.02 for all comparisons). When studies that included a new oral anticoagulant (n=30; all published after 2003) were analysed exclusively, only eight (26.7%) reported ≥2 VKA control measures (mean/study=1.37±0.72). At the same time, however, TTR was reported in all but five studies. Finally, AF and observational studies were more likely to report less common metrics, such as extended range time in the therapeutic range, INR testing interval and frequency of INR monitoring (p\<0.05 for all comparisons).

###### 

Types and frequency of VKA control measures reported in identified studies

  ----------------------------------------------------------
  Variable                                      (N=148)\
                                                n (%)
  --------------------------------------------- ------------
  Number of measures reported (mean±SD)         2.13±1.36

   1                                            63 (42.6)

   2                                            44 (29.7)

   3                                            16 (10.8)

   4                                            13 (8.8)

   5                                            8 (5.4)

   6                                            3 (2.0)

   7                                            1 (0.7)

   ≥2                                           85 (57.4)

  Percentage of time in range (INR=2--3)        117 (79.1)

   Below range (\<2)                            77 (52.0)

   Above range (\>3)                            77 (52.0)

   In extended range (1.8--3.2)                 15 (10.1)

   In extreme range (\<1.5, \>5)                19 (12.8)

  Proportion of INR tests in range (INR=2--3)   24 (16.2)

   Below range (\<2)                            22 (14.9)

   Above range (\>3)                            20 (13.5)

   In extreme range (\<1.5, \>4)                11 (7.4)

  Mean/median INR                               38 (25.7)

  Mean/median VKA dose                          17 (11.5)

  Frequency of INR monitoring                   38 (25.7)

  INR variability                               8 (5.4)

  INR testing interval                          32 (21.6)

  Proportion of patients in/out of range\*      29 (19.6)

  Other†                                        13 (8.8)
  ----------------------------------------------------------

\*For example, point prevalence, proportion of patients in range \>50% of time or proportion of patients with ≥50% of INR measures \<3.0.

†Other measures include: number of dosage changes; INR measure after a previously subtherapeutic or supratherapeutic INR; proportion of patients with ≥1INR measure below range after reaching an adequate INR; number of days until the next INR measure after an extreme measure; proportion of days with treatment stability (two consecutive INR measures in range); days to reach a therapeutic INR; mean time until stable (6 months within target INR range); minimum and maximum INR values per patient.

INR, international normalised ratio; VKA, vitamin K antagonist.

###### 

Differences in VKA control measures reported between AF and VTE studies

  -------------------------------------------------------------------------------------
  Variable                                      AF (N=106)\   VTE (N=49)\   p Value\*
                                                n (%)         n (%)         
  --------------------------------------------- ------------- ------------- -----------
  Number of measures reported (mean±SD)         2.36±1.44     1.53±0.92     \<0.001

   1                                            39 (36.8)     31 (63.3)     

   2                                            30 (28.3)     13 (26.5)     

   3                                            13 (12.3)     4 (8.2)       

   4                                            13 (12.3)     0             

   5                                            8 (7.5)       0             

   6                                            2 (1.9)       1 (2.0)       

   7                                            1 (0.9)       0             

   ≥2                                           67 (63.2)     18 (36.7)     0.004

  Percentage of time in range (INR=2--3)        87 (82.1)     36 (73.5)     0.31

   Below range (\<2)                            53 (50.0)     25 (51.0)     0.96

   Above range (\>3)                            54 (51.0)     24 (49.0)     0.96

   In extended range (1.8--3.2)                 15 (14.2)     0             0.01

   In extreme range (\<1.5, \>5)                13 (12.3)     6 (12.2)      0.80

  Proportion of INR tests in range (INR=2--3)   18 (17.0)     7 (14.3)      0.85

   Below range (\<2)                            16 (15.1)     7 (14.3)      0.91

   Above range (\>3)                            14 (13.2)     7 (14.3)      0.94

   In extreme range (\<1.5, \>4)                11 (10.4)     0             0.05

  Mean/median INR                               30 (28.3)     8 (16.3)      0.16

  Mean/median VKA dose                          15 (14.2)     3 (6.1)       0.24

  Frequency of INR monitoring                   32 (30.2)     7 (14.3)      0.06

  INR variability                               8 (7.5)       0             0.11

  INR testing interval                          29 (27.4)     4 (8.2)       0.01

  Proportion of patients in/out of range†       20 (18.9)     9 (18.4)      0.88

  Other‡                                        11 (10.4)     2 (4.1)       0.32
  -------------------------------------------------------------------------------------

\*p Value for the comparison of AF vs VTE.

†For example, point prevalence, proportion of patients in range \>50% of time or proportion of patients with ≥50% of INR measures \<3.0.

‡Other measures include: number of dosage changes; INR measure after a previously subtherapeutic or supratherapeutic INR; proportion of patients with ≥1INR measure below range after reaching an adequate INR; number of days until the next INR measure after an extreme measure; proportion of days with treatment stability (two consecutive INR measures in range); days to reach a therapeutic INR; mean time until stable (6 months within target INR range); minimum and maximum INR values per patient.

AF, atrial fibrillation; INR, international normalised ratio; VKA, vitamin K antagonist; VTE, venous thromboembolism.

###### 

Differences in VKA control measures reported between randomised trials and observational studies

  -------------------------------------------------------------------------------------------------------
  Variable                                      Randomised\          Observational studies\   p Value\*
                                                controlled trials\   (N=76)\                  
                                                (N=72)\              n (%)                    
                                                n (%)                                         
  --------------------------------------------- -------------------- ------------------------ -----------
  Number of measures reported (mean±SD)         1.63±1.08            2.58±1.46                \<0.001

   1                                            48 (66.7)            18 (23.7)                

   2                                            12 (16.7)            29 (38.2)                

   3                                            6 (8.3)              10 (13.2)                

   4                                            3 (4.2)              10 (13.2)                

   5                                            3 (4.2)              5 (6.6)                  

   6                                            0                    3 (3.9)                  

   7                                            0                    1 (1.3)                  

   ≥2                                           24 (33.3)            58 (76.3)                \<0.001

  Percentage of time in range (INR=2--3)        56 (77.8)            61 (80.3)                0.87

  Proportion of INR tests in range (INR=2--3)   10 (13.9)            14 (18.4)                0.60

  Mean/median INR                               14 (19.4)            24 (31.6)                0.09

  Mean/median VKA dose                          6 (8.3)              11 (14.5)                0.36

  Frequency of INR monitoring                   8 (11.1)             30 (39.5)                \<0.001

  INR variability                               2 (2.8)              6 (7.9)                  0.31

  INR testing interval                          6 (8.3)              24 (31.6)                \<0.001

  Proportion of patients in/out of range†       13 (18.1)            16 (21.1)                0.80

  Other‡                                        2 (2.8)              10 (13.2)                0.04
  -------------------------------------------------------------------------------------------------------

\*p Value for the comparison of randomised controlled trials vs observational studies.

†For example, point prevalence, proportion of patients in range \>50% of time or proportion of patients with ≥50% of INR measures \<3.0.

‡Other measures include: number of dosage changes; INR measure after a previously subtherapeutic or supratherapeutic INR; proportion of patients with ≥1INR measure below range after reaching an adequate INR; number of days until the next INR measure after an extreme measure; proportion of days with treatment stability (two consecutive INR measures in range); days to reach a therapeutic INR; mean time until stable (6 months within target INR range); minimum and maximum INR values per patient.

INR, international normalised ratio; VKA, vitamin K antagonist.

###### 

Change in VKA control measures reported in studies published between 2000--2003 and 2004--2013

  ----------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                      Studies published in 2000--2003 (N=23)\   Studies published in 2004--2013 (N=125)\   p Value\*
                                                n (%)                                     n (%)                                      
  --------------------------------------------- ----------------------------------------- ------------------------------------------ -----------
  Number of measures reported (mean±SD)         1.48±0.79                                 2.23±1.43                                  0.02

   1                                            15 (65.2)                                 51 (40.8)                                  

   2                                            6 (26.1)                                  35 (28.0)                                  

   3                                            1 (4.3)                                   15 (12.0)                                  

   4                                            1 (4.3)                                   12 (9.6)                                   

   5                                            0                                         8 (6.4)                                    

   6                                            0                                         3 (2.4)                                    

   7                                            0                                         1 (0.8)                                    

  ≥2                                            8 (34.8)                                  74 (59.2)                                  0.05

  Percentage of time in range (INR=2--3)        15 (65.2)                                 102 (81.6)                                 0.14

  Proportion of INR tests in range (INR=2--3)   4 (17.4)                                  20 (16.0)                                  0.89

  Mean/median INR                               7 (30.4)                                  31 (24.8)                                  0.76

  Mean/median VKA dose                          1 (4.3)                                   16 (12.8)                                  0.42

  Frequency of INR monitoring                   2 (8.7)                                   36 (28.8)                                  0.08

  INR variability                               0                                         8 (6.4)                                    0.46

  INR testing interval                          4 (17.4)                                  26 (20.8)                                  0.98

  Proportion of patients in/out of range†       1 (4.3)                                   28 (22.4)                                  0.09

  Other‡                                        0                                         12 (9.6)                                   0.26
  ----------------------------------------------------------------------------------------------------------------------------------------------

\*p Value for the comparison of studies published in 2000--2003 vs 2004--2013.

† For example, point prevalence, proportion of patients in range \>50% of time or proportion of patients with ≥50% of INR measures \<3.0.

‡Other measures include: number of dosage changes; INR measure after a previously subtherapeutic or supratherapeutic INR; proportion of patients with ≥1INR measure below range after reaching an adequate INR; number of days until the next INR measure after an extreme measure; proportion of days with treatment stability (two consecutive INR measures in range); days to reach a therapeutic INR; mean time until stable (6 months within target INR range); minimum and maximum INR values per patient.

INR, international normalised ratio; VKA, vitamin K antagonist.

Our assessment of the concomitant use of VKA control measures in identified studies suggested there was little consistency in their use ([figure 2](#BMJOPEN2014005379F2){ref-type="fig"}). TTR (the most frequently reported measure overall) was most often reported with mean INR, frequency of INR monitoring and INR testing interval.

![Frequency of concomitant reporting of vitamin K antagonist (VKA) control measures in identified studies. The width of the line is proportional to the number of trials reporting each pair of VKA control measures. Each node is proportional to the total number of times the VKA control measure was reported. INR, international normalised ratio.](bmjopen2014005379f02){#BMJOPEN2014005379F2}

Discussion {#s4}
==========

We performed a systematic review to assess the degree of standardisation of VKA control measures reported in AF and VTE studies since 2000, and to determine the proportion of studies reporting ≥2 control measures. We found that while TTR was frequently reported in identified studies; other measures were more sporadically provided. Our analysis also demonstrated AF studies (compared with VTE studies), observational studies (compared with randomised trials) and more recently published studies (2004--2013) (compared with older ones) were more likely to report ≥2 VKA control measures per study and report a greater absolute number of measures per study. New oral anticoagulant studies utilised TTR quite frequently (\>80% of the time), suggesting further standardisation in VKA control measure reporting. Finally, we observed little consistency in the combinations of measures used in identified studies.

We believe the results of our systematic review extend current knowledge regarding the frequency and consistency of VKA control measure reporting in anticoagulation studies, and can serve as a valuable tool for clinical trialists and systematic reviewers. The aforementioned review performed by Fitzmaurice *et al*[@R15] included only 15 studies across varying indications (not just AF and VTE), making it only a fraction of the size of our own and suggesting that direct comparison between these systematic reviews should be made with caution. Fitzmaurice *et al* found 60% of VKA studies published between 1995 and 1999 reported ≥2 control measures (mean=1.93/study), but with a wide variation in the type of measures reported. TTR (47%), mean/median INR (33%), PINRR (40%) and mean/median warfarin dose (33%) were the most frequently reported VKA control measures identified in their review; however, none of their studies reported point prevalence despite its easy calculation and recommended use at the time.[@R158]

While our systematic review appears to confirm a number of findings of Fitzmaurice *et al*, our review also suggests that since 2000, additional measures of VKA control---including point prevalence---have become at least to some degree more common in the anticoagulation literature. Moreover, our findings of discrepancies in the number of control measures reported between AF and VTE studies and observational and randomised studies are novel.

There are a number of reasons why reporting multiple measures of VKA control in anticoagulation studies (as originally suggested by Fitzmaurice *et al*) seems wise. First, by reporting multiple measures of control, the likelihood that potentially comparable studies share at least one measure in common is increased. Furthermore, studies suggesting different VKA control measures may yield disparate findings even when utilised in the same patient population.[@R16] In a retrospective cohort study of 633 patients undergoing anticoagulation with a VKA, Schmitt *et al*[@R17] observed 24%, 24% and 22% absolute differences between TTR and PINRR estimates of INR control and 22%, 26% and 17% absolute differences between TTR and point prevalence (cross-sectional) estimates of INR control after 2-month, 3-month and 6-month time intervals of follow-up, respectively. Moreover, in a randomised trial of 367 patients receiving a VKA, Fitzmaurice *et al*[@R16] demonstrated up to a 9% variance between TTR, point prevalence and PINRR estimates in the same population. Finally, a retrospective study of 1511 patients performed by Ansell *et al*[@R18] provided yet more evidence to support population differences in VKA control estimates when different measures are used, demonstrating a 5--10% absolute difference between TTR and PINRR estimates for patients from five different countries.

A final reason for including multiple measures on VKA control in anticoagulation studies is that different VKA control measures have their own unique strengths and weaknesses.[@R17] While TTR takes into account actual days in the target INR range (typically by assuming values vary linearly between two measures[@R19]), its calculation is more complex than other measures; it makes assumptions about INR values between actual tests and can be biased by extreme out-of-range INR values. In addition, while we were not able to assess this in our systematic review because of a lack of consistent reporting, there appears to be variability in what INR values are included in TTR calculations, with some studies excluding INR values occurring during the initiation phase (ie, first week) and/or around temporary interruptions of a VKA.[@R6] [@R8] PINRR is a simpler measure to calculate than TTR; it requires only one INR measurement per patient and is not influenced by the extent INRs are out of range; nevertheless, it fails to take into account actual days of anticoagulation like TTR and may underestimate control when more frequent INR testing occurs in unstable patients. Point prevalence is perhaps the simplest measure to calculate because it takes only one time point into consideration (a cross-sectional method), and like PINRR, it is not influenced by the extent an INR value is out of range; however, unlike the aforementioned methods, point prevalence takes individual patients into account. Finally, it is worth noting that VKA control measures may tend to stabilise over time, suggesting duration of study follow-up should be considered when interpreting a control measure.

On the basis of the results of our systematic review, we agree with the previous recommendation of Fitzmaurice *et al* of reporting at least two measures of VKA control. However, we would like to emphasise that while we recommend multiple measures be reported, we are by no means suggesting that the quantity of measures reported is more important than the quality of the measures. For this reason, we further suggest TTR be one of the measures because of its frequent study in the literature (use in studies and linkage to anticoagulation outcomes).

There are several limitations of our systematic review worth discussion. First, like any other systematic review, the possibility that we missed eligible studies could exist. However, we consider this risk to be minimal due to our systematic search strategy and manual backwards citation tracking. In addition, the large number of included studies in this review lessens the impact that missed studies might have on our overall conclusions. Next, it is reasonable to question the inclusion of mean/median warfarin dose as a true measure of VKA control, since unlike other measures, it does not consider INR values. However, we opted to include it as a measure in order to stay consistent with the methods of the prior review by Fitzmaurice *et al*.[@R15] Finally, the possibility that journal word limits may have played some role in the under-reporting of VKA control measures should be considered.

Conclusions {#s5}
===========

VKA studies lack consistency in the types and combinations of control measures reported. A trend towards studies reporting greater numbers of VKA control measures over time was observed over our review time horizon, particularly, with AF and observational studies. The findings of this systematic review should be taken into consideration by researchers when performing future work in this area.
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